Selectivity and therapeutic inhibition of kinases: to be or not to be? - Test2 - elhamkhani - TriplyDB

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Selectivity and therapeutic inhibition of kinases: to be or not to be?

http://www.wikidata.org/entity/Q24656006

about

Recent advances in understanding psoriasis Jakpot! New small molecules in autoimmune and inflammatory diseases Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor Mechanisms of drug resistance in kinases.Peptide substrates for Rho-associated kinase 2 (Rho-kinase 2/ROCK2)A computational approach to finding novel targets for existing drugs STATs in cancer inflammation and immunity: a leading role for STAT3 Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Identification of novel signaling components in N,N'-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma by quantitative phosphoproteomics.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.Tyrosine kinases in inflammatory dermatologic disease.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression Chemical proteomics: terra incognita for novel drug target profiling.Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.Fragment screening of cyclin G-associated kinase by weak affinity chromatography.Chemical interrogation of the neuronal kinome using a primary cell-based screening assay.STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.Janus kinase-3 dependent inflammatory responses in allergic asthma Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma Increased HCMV seroprevalence in patients with hepatocellular carcinoma.Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.Inhibitory Effect of Curcumol on Jak2-STAT Signal Pathway Molecules of Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis Mechanisms of Jak/STAT signaling in immunity and disease Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma IL-2 regulates expression of C-MAF in human CD4 T cells The use of novel selectivity metrics in kinase research.JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.The dynamics of signaling as a pharmacological target.Navigating the network: signaling cross-talk in hematopoietic cells.Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.

P2860

Q26751223-F24A7888-EC54-4D51-A72F-9B4C91020EC8 Q27001957-FFCB2A19-7F47-43D2-8196-30552274EC8F Q27673465-C6AB0C59-EBA7-4B30-8E72-E5CD7C9A8444 Q27692567-39839582-7FDE-4E4F-833B-5E2949F82DE5 Q28476345-2F3CABF8-8B6B-4409-9310-ACD6620FD2F8 Q28476770-F02CD21C-A55A-4D64-8D4B-57381DA5756B Q29547203-57444B41-8070-4374-A175-A2C8770ACC63 Q30426853-61746CDE-165E-4179-8B74-7A7B8CA66BE4 Q33756524-35772C42-FDF9-4375-A22F-5847EB3BFEB0 Q33913996-B26ADFE6-A16C-4285-932D-644E5D097068 Q33925323-0739C400-34A0-4E1E-AB1F-B695C6A9634E Q33932779-4BF24086-46BD-48AD-99D2-BEF2AAEA281A Q34024820-2850D7D1-5EC2-489D-92E7-D75BF1B3EF2A Q34084020-5108EEE2-FF52-4930-9DA5-69598725A21C Q34166503-34F50BBA-9C57-4162-A157-1EE72539C739 Q34169114-7FB38B2F-C36E-4820-9E1F-CD555ED0864D Q34175958-D1EA6386-9C8A-43D3-91DE-66621583D240 Q34284580-19F3DF7B-E611-4F33-88F5-6B4D6295AA8A Q34359495-DF5EF549-8F9A-4C2E-9E89-4412A1DA92BD Q34392316-3D5BB720-D6F1-4BBE-8C06-B6E53E87D27C Q34616753-6822A712-041F-44FB-A75F-3DBB03246142 Q34936215-4C99E84A-F800-48BF-920D-CFE56E551E6E Q35031161-48A51A04-1258-4732-97F2-32B4CFC4E417 Q35033957-0C9C0877-1AA6-47FA-BCA9-CFD4DADC071C Q35080328-DF1B0A10-D837-415A-8D97-8CA2C43CBC4F Q35178124-DD735A4E-8419-452A-B076-DED410348A44 Q35346411-12CABC4F-E7D1-49AD-AEE7-628761945D5B Q35574918-F6D08D6C-8864-4AF7-B8E3-8625F6141A2B Q35822851-DD638FBF-A9D5-41CC-A3E5-8A34C72CBA32 Q35846015-28924F30-3094-41B3-BDE0-AE1620BF6C6D Q35915068-88660884-FD05-4BCE-93CE-BF720E970068 Q35923178-D1349DCC-1AD3-4304-ACA1-21C50F5202F5 Q36150570-63775F34-2020-475D-ABD8-9A49DE58D6B4 Q36205754-EF14641A-AAE8-4894-B337-280E6C8C48B5 Q36240657-344C2EE8-AEF1-4228-97EC-EA1FA0054C94 Q36404704-FF56176B-D416-4F37-AD4E-C0E01A1FD876 Q37376115-47FAE5C8-0A17-402B-8CC9-94FD2208B041 Q37417479-E759D577-A5CE-4FDE-97A4-19FA2B473463 Q37521242-2B7C7B86-C531-42A6-B63D-D41B6A31BD9A Q37606284-83556E7D-0658-45C3-B787-01144736CF51

P2860

Selectivity and therapeutic inhibition of kinases: to be or not to be?

http://www.wikidata.org/entity/Q24656006

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@ast

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@en

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@nl

type

label

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@ast

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@en

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@nl

prefLabel

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@ast

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@en

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@nl

P1433

Q24656006-4C3A557A-AA5D-43B0-A46F-01E09137D0B2

P1476

Q24656006-B67B0E1F-C51B-4A2A-B4F7-50466CE6B835

P2093

Q24656006-7FBD77F6-A679-43F9-B196-5DF407C835FD

Q24656006-8ADDA91A-9D23-4EEE-903D-826BC251469D

Q24656006-E3C22C89-3EC4-42F2-98E2-ABA9B287418C

P2860

Q24656006-099EF59C-FEBC-406B-A8AC-072FA4169AAC

Q24656006-13B24AFF-275D-43A9-87DC-925FECB4C1C1

Q24656006-18CDC3AC-9FE5-46E8-94B4-CC51BE6E664A

Q24656006-1FAAB1C8-EBD8-4AAF-B368-6B5160D05ED1

Q24656006-256B87C9-5D87-4BBA-9FF6-D7B2F0B170CC

Q24656006-3031C23B-2411-49FB-84AA-A90068F753F4

Q24656006-3367DA8C-D0FF-4071-919D-3A43C509B541

Q24656006-3DEBB2C7-C326-47F9-89DC-0C8544ABF892

Q24656006-42DC9D59-F429-4DF9-BC23-0FB3F4689630

Q24656006-561F7511-12A2-4593-AE47-54D6F2CC6B8A

P304

Q24656006-2FD8B223-3A2F-4F7D-86DC-732B4AED1A73

P31

Q24656006-65D1BF87-852A-4DB0-A80A-3BA6C06D066F

P3181

Q24656006-F6C852F9-E3FC-405B-B573-5927480A7F3C

P356

Q24656006-E9101C4E-428A-4C59-974D-018B69D87445

P407

Q24656006-7423C2CB-E988-44EE-80FB-60EFD14EE5AE

P433

Q24656006-F3B2C05E-582D-42F5-8F7A-0FDAE771BC77

P478

Q24656006-4C91EB5E-A2C6-455A-8037-66FD58168D0A

P577

Q24656006-194F478B-52E1-40DF-BFF9-08A90F7B4F51

P5875

Q24656006-5DECA977-47B0-46BA-A1F6-23DC8CECAC16

P698

Q24656006-5A32F375-2218-452B-A536-594E8B40EB1E

P932

Q24656006-F5528849-CEB9-4C48-A97E-668888D8F7F7

P3181

P356

P1433

Nature Immunology

P1476

Selectivity and therapeutic inhibition of kinases: to be or not to be?

@en

P2093

Arian Laurence

http://www.w3.org/2001/XMLSchema#string

John J O'Shea

http://www.w3.org/2001/XMLSchema#string

Kamran Ghoreschi

http://www.w3.org/2001/XMLSchema#string

P2860

The Sequence of the Human Genome

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

The protein kinase complement of the human genome

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

P304

356-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2010432

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NI.1701

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24209607

http://www.w3.org/2001/XMLSchema#string

P698

19295632

http://www.w3.org/2001/XMLSchema#string

P932

2758543

http://www.w3.org/2001/XMLSchema#string